Cell cycle regulation and the function of cancer genes

Metabolic heterogeneity-based radiomic model predicts treatment outcomes of primary mediastinal B-cell lymphoma patients in the IELSG37 study.

British journal of haematology·2026

Left and right-side echocardiographic measurement of pulmonary artery stiffness in thoroughbred racehorses.

Journal of equine veterinary science·2026

Baseline PET radiomics outperforms the IPI risk score for prediction of outcome in diffuse large B-cell lymphoma.

Blood·2023

A systematic review of contemporary phase I trials in patients with lymphoma.

Critical reviews in oncology/hematology·2022

Cost-Effectiveness of Shortening Treatment Duration Based on Interim PET Outcome in Patients With Diffuse Large B-cell Lymphoma.

Clinical lymphoma, myeloma & leukemia·2021

Optimal timing and criteria of interim PET in DLBCL: a comparative study of 1692 patients.

Blood advances·2021

Ovarian reserve as a measure of adjuvant chemotherapy benefit in hormone receptor positive (HR-positive), HER2-negative, node-positive breast cancer in SWOG S1007 (RxPONDER).

Annals of oncology : official journal of the European Society for Medical Oncology·2026

Therapeutic targeting of RAS-mediated resistance in oncogene-driven lung cancer.

Annals of oncology : official journal of the European Society for Medical Oncology·2026

Eight-year outcomes of testosterone suppression plus enzalutamide or a non-steroidal anti-androgen for metastatic, hormone-sensitive prostate cancer (ENZAMET; ANZUP 1304).

Annals of oncology : official journal of the European Society for Medical Oncology·2026

Nivolumab plus chemotherapy or ipilimumab versus chemotherapy as first-line treatment for advanced esophageal squamous cell carcinoma: 5-year follow-up results from CheckMate 648.

Annals of oncology : official journal of the European Society for Medical Oncology·2026

SKYSCRAPER-03: A Phase III Study of Tiragolumab Plus Atezolizumab Versus Durvalumab in Locally Advanced, Unresectable, Stage III NSCLC After Platinum-Based Concurrent Chemoradiation.

Annals of oncology : official journal of the European Society for Medical Oncology·2026

A multimodal deep learning model for preoperative prediction of post-operative complications in gastric cancer.

Annals of oncology : official journal of the European Society for Medical Oncology·2026

Single-cell and spatial omics of metabolic-immune ecosystems in prostate cancer: from androgen signaling to therapy resistance.

Frontiers in immunology·2026

Cyclooxygenases in pancreatic ductal adenocarcinoma: are they inflammatory catalysts for tumor growth.

Frontiers in oncology·2026

Host-virus resilience networks and viral inflammaging circuits in aging and long COVID: a CMV-centered perspective.

Frontiers in cellular and infection microbiology·2026

Unravelling the nexus of non-coding RNAs in cancer stemness and therapeutic drug resistance.

Frontiers in cell and developmental biology·2026

Updated oncolytic viruses for the treatment of bladder cancer: a systematic review.

Iranian journal of microbiology·2026

The Impact of Chronic Kidney Disease on Postoperative Outcomes in Patients With Bladder Cancer: A Meta-Analysis.

Clinical Medicine Insights. Oncology·2026

Related Experiment Videos

Cell cycle regulation and the function of cancer genes

Related Concept Videos

Metabolic heterogeneity-based radiomic model predicts treatment outcomes of primary mediastinal B-cell lymphoma patients in the IELSG37 study.

Left and right-side echocardiographic measurement of pulmonary artery stiffness in thoroughbred racehorses.

Baseline PET radiomics outperforms the IPI risk score for prediction of outcome in diffuse large B-cell lymphoma.

A systematic review of contemporary phase I trials in patients with lymphoma.

Cost-Effectiveness of Shortening Treatment Duration Based on Interim PET Outcome in Patients With Diffuse Large B-cell Lymphoma.

Optimal timing and criteria of interim PET in DLBCL: a comparative study of 1692 patients.

Ovarian reserve as a measure of adjuvant chemotherapy benefit in hormone receptor positive (HR-positive), HER2-negative, node-positive breast cancer in SWOG S1007 (RxPONDER).

Therapeutic targeting of RAS-mediated resistance in oncogene-driven lung cancer.

Eight-year outcomes of testosterone suppression plus enzalutamide or a non-steroidal anti-androgen for metastatic, hormone-sensitive prostate cancer (ENZAMET; ANZUP 1304).

Nivolumab plus chemotherapy or ipilimumab versus chemotherapy as first-line treatment for advanced esophageal squamous cell carcinoma: 5-year follow-up results from CheckMate 648.

SKYSCRAPER-03: A Phase III Study of Tiragolumab Plus Atezolizumab Versus Durvalumab in Locally Advanced, Unresectable, Stage III NSCLC After Platinum-Based Concurrent Chemoradiation.

A multimodal deep learning model for preoperative prediction of post-operative complications in gastric cancer.

Single-cell and spatial omics of metabolic-immune ecosystems in prostate cancer: from androgen signaling to therapy resistance.

Cyclooxygenases in pancreatic ductal adenocarcinoma: are they inflammatory catalysts for tumor growth.

Host-virus resilience networks and viral inflammaging circuits in aging and long COVID: a CMV-centered perspective.

Unravelling the nexus of non-coding RNAs in cancer stemness and therapeutic drug resistance.

Updated oncolytic viruses for the treatment of bladder cancer: a systematic review.

The Impact of Chronic Kidney Disease on Postoperative Outcomes in Patients With Bladder Cancer: A Meta-Analysis.

Related Experiment Videos

Cell cycle regulation and the function of cancer genes

Related Concept Videos

Related Articles